AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

BeOne Medicines AG

$346.51 +$35.49 (+11.41%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$341.8
Day Range
$341.22$349.08
Year Range
$253.95$385.22
Market Cap
37.03B
AVG Volume
344.27K
Trailing/Forward PE
25.55/34.12
PEG ratio
0.7
Dividend Yield
-
Next Earnings Date
2026-11-05
Primary Exchange
NASDAQUS
Revenue (USD)
02B4B6B2016201720182019202020212022202320242025
ONC Revenue (USD) by year
PeriodRevenue (USD)
20255.34B
20243.81B
20232.46B
20221.42B
20211.18B
2020308.87M
2019428.21M
2018198.22M
2017238.39M
20161.07M
Net Income (USD)
-3B-2B-1B01B2016201720182019202020212022202320242025
ONC Net Income (USD) by year
PeriodNet Income (USD)
2025286.93M
2024-644.79M
2023-881.71M
2022-2B
2021-1.44B
2020-1.6B
2019-948.63M
2018-673.77M
2017-93.11M
2016-119.22M
Operating Income (USD)
-2B-1B01B2016201720182019202020212022202320242025
ONC Operating Income (USD) by year
PeriodOperating Income (USD)
2025447.14M
2024-568.2M
2023-1.21B
2022-1.79B
2021-1.44B
2020-1.66B
2019-959.89M
2018-705.77M
2017-98.46M
2016-117.06M
EBITDA (USD)
-2B-1B01B2016201720182019202020212022202320242025
ONC EBITDA (USD) by year
PeriodEBITDA (USD)
2025629.29M
2024-362.06M
2023-738.16M
2022-1.89B
2021-1.37B
2020-1.63B
2019-941.27M
2018-695.38M
2017-93.7M
2016-115.15M
Cash Flows (USD)
-2B-1B01B2016201720182019202020212022202320242025
ONC Cash Flows (USD) by year
PeriodCash Flows (USD)
2025613.19M
2024-669.77M
2023-1.75B
2022-1.97B
2021-1.61B
2020-1.51B
2019-908.88M
2018-688.55M
2017-45.98M
2016-113.02M
EPS (USD)
-60-40-20020402016201720182019202020212022202320242025
ONC EPS (USD) by year
PeriodEPS (USD)
202521.13
2024-6.21
2023-30.55
2022-45.76
2021-15.08
2020-18.98
2019-15.73
2018-11.96
2017-2.44
2016-3.44
Expenses (USD)
02B4B6BR&DSG&ACapex2016201720182019202020212022202320242025
ONC Expenses (USD) by year
PeriodExpenses (USD)
20254.74B
20244.31B
20233.88B
20223.39B
20212.76B
20202.12B
20191.47B
20181.02B
2017390.35M
2016141.63M
Cash & Debt (USD)
02B4B6B8BCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
ONC Cash & Debt (USD) by year
PeriodCash & Debt (USD)
20254.55B
20242.63B
20233.17B
20224.53B
20216.62B
20204.65B
2019982.74M
20181.78B
2017837.52M
2016368.17M
Debt ratios
00.511.5220182019202020212022202320242025
ONC Debt ratios by year
PeriodDebt ratios
20251.08
20240.35
20230.4
20220.68
20211.28
20201.22
20190.38
20181.65
Margins
-10000%-7500%-5000%-2500%0%2500%2016201720182019202020212022202320242025
ONC Margins by year
PeriodMargins
202587.49%
202484.41%
202384.55%
202279.77%
202185.98%
202077.12%
2019-67.04%
2018-257.03%
2017-14.94%
2016-9061.96%
Return on Capital
-100%-50%0%50%2016201720182019202020212022202320242025
ONC Return on Capital by year
PeriodReturn on Capital
20256.58%
2024-19.35%
2023-24.93%
2022-45.71%
2021-23.44%
2020-41.27%
2019-96.96%
2018-38.11%
2017-13.33%
2016-33.78%
Shares Outstanding
050M100M150M2016201720182019202020212022202320242025
ONC Shares Outstanding by year
PeriodShares Outstanding
2025109.06M
2024106.26M
2023104.08M
2022103.76M
202195.03M
202090.85M
201960.68M
201859.38M
201745.54M
201639.68M
Book Value Per Share (USD)
0204060802016201720182019202020212022202320242025
ONC Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
202539.99
202431.36
202333.99
202242.24
202164.54
202042.59
201916.12
201829.77
201715.34
20168.89
Total Assets (USD)
02.5B5B7.5B10B2016201720182019202020212022202320242025
ONC Total Assets (USD) by year
PeriodTotal Assets (USD)
20258.19B
20245.92B
20235.81B
20226.38B
20218.54B
20205.6B
20191.61B
20182.25B
20171.05B
2016405.81M
Employee Count
05K10K15K2016201720182019202020212022202320242025
ONC Employee Count by year
PeriodEmployee Count
202512K
202411K
202310.6K
20229.2K
20218.2K
20205.3K
20193.5K
20182.2K
2017900
2016348
PE Ratio
0200400600med 111.69Nov 25Jan 26Feb 26Apr 26Jun 26Jul 26Sep 26
ONC PE Ratio by year
PeriodPE Ratio
Sep 2658.96
Sep 2660.96
Aug 2662.4
Aug 2663.72
Aug 2659.13
Aug 2659.26
Jul 2668.35
Jul 2670.49
Jul 2667.48
Jul 2664.6
Jul 2664.38
Jun 2660.54
Jun 2658.43
Jun 2657.2
Jun 2658.42
May 2662.27
May 2667.1
May 2663.43
May 2667.51
May 26111.69
Apr 26114.33
Apr 26123.1
Apr 26117.7
Apr 26118.13
Mar 26107.58
Mar 26104.63
Mar 26107.97
Mar 26114.45
Feb 26120.49
Feb 26582.25
Feb 26556.42
Feb 26569.04
Jan 26547.27
Jan 26545.56
Jan 26543.75
Jan 26543.26
Jan 26500.06
Dec 25502.26
Dec 25508.15
Dec 25512.99
Dec 25519.16
Nov 25547.64
Nov 25559.07
Nov 25588.17
Nov 25514.45
Free Cash Flow Yield
-10%-5%0%5%med 0.48%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ONC Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 263.21%
Sep 263.11%
Aug 263.04%
Aug 262.97%
Aug 263.21%
Aug 263.2%
Jul 262.41%
Jul 262.34%
Jul 262.45%
Jul 262.55%
Jul 262.56%
Jun 262.73%
Jun 262.82%
Jun 262.88%
Jun 262.82%
May 262.65%
May 262.46%
May 262.6%
May 262.44%
May 261.91%
Apr 261.87%
Apr 261.74%
Apr 261.82%
Apr 261.81%
Mar 261.99%
Mar 262.04%
Mar 261.98%
Mar 261.87%
Feb 261.77%
Feb 261.16%
Feb 261.22%
Feb 261.19%
Jan 261.24%
Jan 261.24%
Jan 261.25%
Jan 261.25%
Jan 261.36%
Dec 251.35%
Dec 251.33%
Dec 251.32%
Dec 251.31%
Nov 251.24%
Nov 251.21%
Nov 251.15%
Nov 251.32%
Oct 250.49%
Oct 250.49%
Oct 250.48%
Oct 250.47%
Oct 250.44%
Sep 250.47%
Sep 250.45%
Sep 250.47%
Sep 250.44%
Aug 250.5%
Aug 250.48%
Aug 250.47%
Aug 250.53%
Aug 25-0.75%
Jul 25-0.77%
Jul 25-0.76%
Jul 25-0.9%
Jul 25-0.92%
Jun 25-0.93%
Jun 25-0.91%
Jun 25-0.83%
Jun 25-0.88%
May 25-0.92%
May 25-2.61%
May 25-2.76%
May 25-2.72%
May 25-2.46%
Apr 25-2.57%
Apr 25-2.73%
Apr 25-2.74%
Apr 25-2.64%
Mar 25-2.36%
Mar 25-2.5%
Mar 25-2.43%
Mar 25-2.55%
Feb 25-3.66%
Feb 25-3.89%
Feb 25-4.31%
Feb 25-4.45%
Jan 25-4.42%
Jan 25-4.48%
Jan 25-4.73%
Jan 25-5.63%
Jan 25-5.5%
Dec 24-5.47%
Dec 24-5.63%
Dec 24-5.54%
Dec 24-4.84%
Nov 24-4.62%
Nov 24-6.8%
Nov 24-6.85%
Nov 24-6.3%
Nov 24-6.34%
Oct 24-6.09%
Oct 24-5.92%
Price to Sales
56789med 6.8Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ONC Price to Sales by year
PeriodPrice to Sales
Sep 266.31
Sep 266.52
Aug 266.68
Aug 266.82
Aug 266.33
Aug 266.34
Jul 266.11
Jul 266.3
Jul 266.03
Jul 265.77
Jul 265.75
Jun 265.41
Jun 265.22
Jun 265.11
Jun 265.22
May 265.57
May 266
May 265.67
May 266.03
May 266
Apr 266.14
Apr 266.61
Apr 266.32
Apr 266.34
Mar 265.78
Mar 265.62
Mar 265.8
Mar 266.15
Feb 266.47
Feb 268.03
Feb 267.67
Feb 267.84
Jan 267.54
Jan 267.52
Jan 267.5
Jan 267.49
Jan 266.89
Dec 256.92
Dec 257
Dec 257.07
Dec 257.16
Nov 257.55
Nov 257.71
Nov 258.11
Nov 257.09
Oct 257.39
Oct 257.4
Oct 257.53
Oct 257.62
Oct 258.18
Sep 257.76
Sep 257.96
Sep 257.72
Sep 258.13
Aug 257.28
Aug 257.47
Aug 257.65
Aug 256.86
Aug 257.66
Jul 257.46
Jul 257.54
Jul 256.41
Jul 256.29
Jun 256.18
Jun 256.33
Jun 256.9
Jun 256.55
May 256.29
May 256.73
May 256.37
May 256.47
May 257.13
Apr 256.83
Apr 256.44
Apr 256.42
Apr 256.65
Mar 257.46
Mar 257.03
Mar 257.23
Mar 256.89
Feb 258.58
Feb 258.06
Feb 257.29
Feb 257.05
Jan 257.1
Jan 257.01
Jan 256.63
Jan 255.58
Jan 255.71
Dec 245.74
Dec 245.57
Dec 245.66
Dec 246.49
Nov 246.79
Nov 246.44
Nov 246.4
Nov 246.95
Nov 246.9
Oct 247.2
Oct 247.4
EV/EBITDA
0100200300med 71.32Aug 25Oct 25Jan 26Mar 26May 26Jul 26Sep 26
ONC EV/EBITDA by year
PeriodEV/EBITDA
Sep 2629.94
Sep 2631.07
Aug 2631.88
Aug 2632.63
Aug 2630.03
Aug 2630.11
Jul 2634.84
Jul 2636.06
Jul 2634.35
Jul 2632.71
Jul 2632.58
Jun 2630.4
Jun 2629.2
Jun 2628.5
Jun 2629.19
May 2631.39
May 2634.13
May 2632.04
May 2634.36
May 2646.88
Apr 2648.08
Apr 2652.08
Apr 2649.62
Apr 2649.81
Mar 2645
Mar 2643.66
Mar 2645.18
Mar 2648.14
Feb 2650.89
Feb 26106.88
Feb 26101.75
Feb 26104.26
Jan 2699.93
Jan 2699.6
Jan 2699.23
Jan 2699.14
Jan 2690.56
Dec 2591
Dec 2592.17
Dec 2593.13
Dec 2594.35
Nov 25100.01
Nov 25102.28
Nov 25108.06
Nov 2593.42
Oct 25239.09
Oct 25239.36
Oct 25243.91
Oct 25246.9
Oct 25266.19
Sep 25251.74
Sep 25258.51
Sep 25250.34
Sep 25264.51
Aug 25235.49
Aug 25241.68
Aug 25247.92
Aug 25220.99
Price/Operating Cashflow
0200400600800med 48.56Apr 18Jul 25Oct 25Jan 26Mar 26Jun 26Sep 26
ONC Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 2622.93
Sep 2623.71
Aug 2624.27
Aug 2624.78
Aug 2623
Aug 2623.05
Jul 2627.28
Jul 2628.13
Jul 2626.93
Jul 2625.78
Jul 2625.69
Jun 2624.16
Jun 2623.32
Jun 2622.83
Jun 2623.31
May 2624.85
May 2626.78
May 2625.31
May 2626.94
May 2628.42
Apr 2629.09
Apr 2631.33
Apr 2629.95
Apr 2630.06
Mar 2627.38
Mar 2626.63
Mar 2627.47
Mar 2629.12
Feb 2630.66
Feb 2650.82
Feb 2648.56
Feb 2649.67
Jan 2647.77
Jan 2647.62
Jan 2647.46
Jan 2647.42
Jan 2643.65
Dec 2543.84
Dec 2544.35
Dec 2544.77
Dec 2545.31
Nov 2547.8
Nov 2548.8
Nov 2551.34
Nov 2544.9
Oct 2559.01
Oct 2559.08
Oct 2560.14
Oct 2560.84
Oct 2565.36
Sep 2561.98
Sep 2563.56
Sep 2561.65
Sep 2564.97
Aug 2558.17
Aug 2559.62
Aug 2561.08
Aug 2554.78
Aug 25150.8
Jul 25146.99
Jul 25148.55
Jul 25126.23
Jul 25123.81
Jun 25121.64
Jun 25124.61
Jun 25135.98
Jun 25129.03
May 25123.85
May 18677.52
May 18694.84
May 18621.94
May 18646.12
Apr 18620.91
Apr 18599.98
Apr 18600.8
Apr 18587.44
Mar 18600.02
Mar 18564.34
Mar 18564.84
Mar 18542.76
Mar 18538.3
Price to Book
46810med 7.67Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ONC Price to Book by year
PeriodPrice to Book
Sep 267.47
Sep 267.73
Aug 267.91
Aug 268.08
Aug 267.49
Aug 267.51
Jul 267.37
Jul 267.6
Jul 267.27
Jul 266.96
Jul 266.94
Jun 266.52
Jun 266.3
Jun 266.16
Jun 266.3
May 266.71
May 267.23
May 266.84
May 267.27
May 267.35
Apr 267.52
Apr 268.1
Apr 267.74
Apr 267.77
Mar 267.08
Mar 266.88
Mar 267.1
Mar 267.53
Feb 267.93
Feb 269.67
Feb 269.24
Feb 269.45
Jan 269.09
Jan 269.06
Jan 269.03
Jan 269.02
Jan 268.3
Dec 258.34
Dec 258.44
Dec 258.52
Dec 258.62
Nov 259.09
Nov 259.28
Nov 259.76
Nov 258.54
Oct 258.94
Oct 258.95
Oct 259.11
Oct 259.22
Oct 259.9
Sep 259.39
Sep 259.63
Sep 259.34
Sep 259.84
Aug 258.81
Aug 259.03
Aug 259.25
Aug 258.3
Aug 259.14
Jul 258.91
Jul 259
Jul 257.65
Jul 257.5
Jun 257.37
Jun 257.55
Jun 258.24
Jun 257.82
May 257.5
May 257.7
May 257.28
May 257.4
May 258.16
Apr 257.81
Apr 257.37
Apr 257.35
Apr 257.61
Mar 258.53
Mar 258.04
Mar 258.27
Mar 257.88
Feb 258.28
Feb 257.78
Feb 257.03
Feb 256.81
Jan 256.86
Jan 256.77
Jan 256.4
Jan 255.38
Jan 255.51
Dec 245.54
Dec 245.38
Dec 245.46
Dec 246.27
Nov 246.55
Nov 245.93
Nov 245.89
Nov 246.39
Nov 246.35
Oct 246.62
Oct 246.81
BeOne Medicines AG
ONC
Stockpicker

Video analysis: ONC

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ONC

BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in Stock

defenseworld.net · 13 Sep 2026

BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC - Get Free Report) insider Xiaodong Wang sold 38,287 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $349.10, for a total value of $13,365,991.70. Following the completion of the sale, the insider directly owned 6,079 shares

Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving Average   – Here’s Why

defenseworld.net · 10 Sep 2026

Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE: ONC - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares. Oncolytics Biotech Price Performance The company has

Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC

defenseworld.net · 8 Sep 2026

Nykredit A S Invests $1.20 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC

Nykredit A S purchased a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,225 shares of the company's stock, valued at approximately $1,204,000. A number of other hedge funds and other

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

zacks.com · 1 Sep 2026

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

businesswire.com · 1 Sep 2026

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Medicin.

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

businesswire.com · 31 Aug 2026

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scien.

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

businesswire.com · 31 Aug 2026

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonst.

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

zacks.com · 27 Aug 2026

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.